BridgeBio Pharma, now a parent company to 18 subsidiaries after its inception in 2017, has closed a $299.2m financing round from new and returning investors – funding that CEO Neil Kumar predicts will extend the company’s runway by two years or more.
Palo Alto, Calif.-based BridgeBio may have underestimated how many opportunities would be available when the firm raised its first $135m...






